Gene therapies for rare eye diseases

A fight against blindness!

News & Press releases

VARIANT Receives Positive Feedback from the European Medicines Agency(EMA) for its Innovative Gene Replacement Therapy, VAR002

Apr 1, 2025

PARIS – Variant and the Rare Ocular Diseases Center at the University of Campania Luigi Vanvitelli (UCLV) in Naples today announced that they have received positive feedback from the European Medicines Agency (EMA) on VAR002, an adeno-associated viral vector gene therapy targeting inherited retinal dystrophies linked to CRX mutations. This consultation and subsequent feedback from…

VARIANT reçoit un avis favorable de l’Agence Européenne des Médicaments (EMA) pour VAR002, sa thérapie génique de remplacement innovante.

Apr 1, 2025

Paris – Variant et le Centre des Maladies Oculaires Rares de l’Université de Campanie Luigi Vanvitelli – UCLV (Naples, Italie), annoncent aujourd’hui avoir reçu un avis favorable de l’EMA. Cette consultation visait à garantir que le plan de développement non clinique de VAR002 est adapté à la réalisation d’un futur essai clinique de première administration…

VARIANT and University of Campania Luigi Vanvitelli partner on pre-clinical studies for VAR002, a gene therapy for CRX-related Inherited retinal diseases.

May 5, 2024

Paris – Variant and the Rare Ocular Diseases Center at the University of Campania Luigi Vanvitelli – UCLV (Naples, Italy) today announce a collaboration to initiate pre-clinical studies to accelerate the development of VAR002. These studies include a Natural History Study in patients with CRX-related retinal dystrophies, GLP/GMP vector production and a pre-clinical toxicological study…

Denis CAYET
CEO

Our research team has demonstrated and patented the therapeutic potential of transcription factors, paving the way for a broader spectrum of treatments for inherited retinal diseases.

The scientific team

Alejandro ESTRADA
Project manager

Elodie-Kim GRELLIER
Effectiveness measurements

Jean-Michel ROZET

Scientific director of genetic
in ophthalmology

Group leader & principal investigator for
"CRX expression variability"

Jérome ROGER

CERTO Researcher

Group leader & principal investigator for
“CRX Over-expression”

Thomas LAMONERIE

IBV Unit director

Group leader & principal investigator for
"Allele-specific inhibition”

Vasiliki KALATZIS

INM Vision team leader

Group leader & principal investigator for
"characterisation of patient derived retinal organoids
+ effactiveness measurement”

Francesca SIMONELLI

Chief of the Eye Clinic at UCLV